MedTrace Logo

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

NCT02597036 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-10-23

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel

Conditions

Interventions

DRUG

LY3127804

Administered IV

DRUG

Ramucirumab

Administered IV

DRUG

Paclitaxel

Administered IV

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-06
Primary Completion
2017-11-23
Completion
2020-05-24

Countries

  • United States
  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02597036 on ClinicalTrials.gov